[Herpes genitalis].
Volpi
A
A
Dipartimento di Sanità Pubblica, Università Tor Vergata, Roma.
Testore
G P
GP
Sarrecchia
C
C
D015075:2-Aminopurine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000212:Acyclovir / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000077595:Famciclovir; D005260:Female; D006558:Herpes Genitalis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D008297:Male; D015995:Prevalence; D011355:Prodrugs / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D013997:Time Factors; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D000998:Antiviral Agents; D011355:Prodrugs; D015075:2-Aminopurine; D014633:Valine; D000077483:Valacyclovir; D000077595:Famciclovir; D000212:Acyclovir